Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2010 5
2011 9
2012 5
2013 4
2014 3
2015 1
2016 2
2017 1
2018 1
2019 6
2020 13
2021 12
2022 10
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Microbiome-derived ethanol in nonalcoholic fatty liver disease.
Meijnikman AS, Davids M, Herrema H, Aydin O, Tremaroli V, Rios-Morales M, Levels H, Bruin S, de Brauw M, Verheij J, Kemper M, Holleboom AG, Tushuizen ME, Schwartz TW, Nielsen J, Brandjes D, Dirinck E, Weyler J, Verrijken A, De Block CEM, Vonghia L, Francque S, Beuers U, Gerdes VEA, Bäckhed F, Groen AK, Nieuwdorp M. Meijnikman AS, et al. Among authors: holleboom ag. Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216942
Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach.
Stols-Gonçalves D, Mak AL, Madsen MS, van der Vossen EWJ, Bruinstroop E, Henneman P, Mol F, Scheithauer TPM, Smits L, Witjes J, Meijnikman AS, Verheij J, Nieuwdorp M, Holleboom AG, Levin E. Stols-Gonçalves D, et al. Among authors: holleboom ag. Gut Microbes. 2023 Dec 31;15(1):2223330. doi: 10.1080/19490976.2023.2223330. Gut Microbes. 2023. PMID: 37317027 Free PMC article.
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, Bedossa P, Geier A, Francque S, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison SA, Chen Y, Cobbold JF, Pavlides M, Holleboom AG, Yki-Jarvinen H, Crespo J, Karsdal M, Ostroff R, Zafarmand MH, Torstenson R, Duffin K, Yunis C, Brass C, Ekstedt M, Aithal GP, Schattenberg JM, Bugianesi E, Romero-Gomez M, Ratziu V, Anstee QM, Bossuyt PM; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Vali Y, et al. Among authors: holleboom ag. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):714-725. doi: 10.1016/S2468-1253(23)00017-1. Epub 2023 Mar 21. Lancet Gastroenterol Hepatol. 2023. PMID: 36958367 Free article.
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk AM, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lupșor-Platon M, Wong VW, Li G, Wong GL, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan WK, Mahadeva S, Rajaram R, Zheng MH, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee DH, Ekstedt M, Nasr P, Cassinotto C, de Lédinghen V, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Martic M, Tuthill T, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M; LITMUS investigators. Mózes FE, et al. Among authors: holleboom ag. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713. doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5. Lancet Gastroenterol Hepatol. 2023. PMID: 37290471 Free article.
Moving Targets: Recent Advances in Lipid-Lowering Therapies.
Larsen LE, Stoekenbroek RM, Kastelein JJP, Holleboom AG. Larsen LE, et al. Among authors: holleboom ag. Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):349-359. doi: 10.1161/ATVBAHA.118.312028. Arterioscler Thromb Vasc Biol. 2019. PMID: 30676072 Free article. Review.
NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. Stols-Gonçalves D, et al. Among authors: holleboom ag. Trends Endocrinol Metab. 2019 Dec;30(12):891-902. doi: 10.1016/j.tem.2019.08.008. Epub 2019 Oct 17. Trends Endocrinol Metab. 2019. PMID: 31630897 Review.
Metabolic dysfunction-associated steatotic liver disease and the heart.
Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, Holleboom AG. Driessen S, et al. Among authors: holleboom ag. Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000735. Online ahead of print. Hepatology. 2023. PMID: 38147315
Implementation of a liver health check in people with type 2 diabetes.
Abeysekera KWM, Valenti L, Younossi Z, Dillon JF, Allen AM, Nourredin M, Rinella ME, Tacke F, Francque S, Ginès P, Thiele M, Newsome PN, Guha IN, Eslam M, Schattenberg JM, Alqahtani SA, Arrese M, Berzigotti A, Holleboom AG, Caussy C, Cusi K, Roden M, Hagström H, Wong VW, Mallet V, Castera L, Lazarus JV, Tsochatzis EA. Abeysekera KWM, et al. Among authors: holleboom ag. Lancet Gastroenterol Hepatol. 2024 Jan;9(1):83-91. doi: 10.1016/S2468-1253(23)00270-4. Lancet Gastroenterol Hepatol. 2024. PMID: 38070521 Review.
83 results